177Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial. - Hallqvist, Andreas; Brynjarsdóttir, Elva; Krantz, Tomas; Sjögren, Marie; Svensson, Johanna; Bernhardt, Peter (Journal of Nuclear Medicine, 2025)